A 1-Year Safety Study of Dulaglutide in Japanese Patients With Type 2 Diabetes on a Single Oral Hypoglycemic Agent: An Open-Label, Nonrandomized, Phase 3 Trial

Endocrine Journal- Japan

doi 10.1507/endocrj.ej15-0401

Full Text

Abstract

Available in

Date

Authors

Publisher

Japan Endocrine Society

Related search

Efficacy and Safety of Repaglinide Added to Sitagliptin in Japanese Patients With Type 2 Diabetes: A Randomized 24-Week Open-Label Clinical Trial

Endocrine Journal
EndocrinologyMetabolismDiabetes
2016English

Efficacy and Safety of Dulaglutide in the Treatment of Type 2 Diabetes: A Comprehensive Review of the Dulaglutide Clinical Data Focusing on the AWARD Phase 3 Clinical Trial Program

Diabetes/Metabolism Research and Reviews
Internal MedicineEndocrinologyMetabolismDiabetes
2016English

Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2014English

Efficacy and Safety of Ipragliflozin Add‐on Therapy to Insulin in Japanese Patients With Type 1 Diabetes Mellitus: A Randomized, Double‐blind, Phase 3 Trial

Diabetes, Obesity and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Association Between Use of Oral Hypoglycemic Agents in Japanese Patients With Type 2 Diabetes Mellitus and Risk of Depression: A Retrospective Cohort Study

Pharmacology Research and Perspectives
ToxicologyNeurologyPharmaceuticsPharmacology
2019English

Association Between Use of Oral Hypoglycemic Agents in Japanese Patients With Type 2 Diabetes Mellitus and Risk of Depression: A Retrospective Cohort Study

Proceedings for Annual Meeting of The Japanese Pharmacological Society
2020English

Efficacy of Combination Therapy With Insulin and Oral Hypoglycemic Agents in Patients With Type II Diabetes During a 1-Year Period

Journal of the American Osteopathic Association, The
MedicineAlternative MedicineComplementary
1996English

Long-Term Safety and Tolerability of Oral Tofacitinib in Patients With Crohn’s Disease: Results From a Phase 2, Open-Label, 48-Week Extension Study

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2019English

A Phase III, Multicenter, Collaborative, Open-Label Clinical Trial of Sildenafil in Japanese Patients With Pulmonary Arterial Hypertension

Circulation Journal
MedicineCardiovascular MedicineCardiology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy